

## CytoSorbents Cp (CTSO- NASDAQ)

### CTSO: Additional Support in Sepsis

<b>Current Recommendation</b>	<b>Outperform</b>
Prior Recommendation	N/A
Date of Last Change	06/04/2012
Current Price (02/26/16)	\$5.03
<b>Target Price</b>	<b>\$11.50</b>

### OUTLOOK

CTSO continues to generate clinical outcomes data which is being used to accelerate adoption and utilization. CTSO now also focused in U.S. regulatory approval – either with a cardiac surgery and/or sepsis indication. Just received notice from FDA that EAP for critical care illness in U.S. not feasible. CTSO now looking at IDE/PMA study for U.S. approval for sepsis.

Recent restructuring of sales force caused a hiccup in sales but looks like was only a short-term issue. Product sales grew 39% from Q2 to Q3. CTSO already made replacements to sales force with 2 add'l hires expected by current year-end. Add'l distributors, including Fresenius and add'l geographic territories to come online shortly should further accelerate product sales. Interest in and use of CytoSorb from hospitals and physicians continues to increase.

### SUMMARY DATA

52-Week High	\$15.24
52-Week Low	\$3.11
One-Year Return (%)	-59.07
Beta	0.43
Average Daily Volume (sh)	70,837

Shares Outstanding (mil)	25
Market Capitalization (\$mil)	\$118
Short Interest Ratio (days)	4.56
Institutional Ownership (%)	5
Insider Ownership (%)	26

Annual Cash Dividend	\$0.00
Dividend Yield (%)	0.00

<b>5-Yr. Historical Growth Rates</b>	
Sales (%)	63.5
Earnings Per Share (%)	N/A
Dividend (%)	N/A

P/E using TTM EPS	N/A
P/E using 2016 Estimate	N/A
P/E using 2017 Estimate	N/A

Zacks Rank	N/A
------------	-----

<b>Risk Level</b>	<b>Above Avg.,</b>
<b>Type of Stock</b>	<b>Small-Growth</b>
<b>Industry</b>	<b>Med Products</b>

### ZACKS ESTIMATES

#### Revenue (in '000 of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	1062 A	1025 A	1162 A	874 A	4123 A
2015	723 A	964 A	1344 A	1454 E	4484 E
2016					12212 E
2017					20245 E

#### Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	-0.20 A	-0.27 A	-0.22 A	-0.47 A	-1.29 A
2015	-0.19 A	0.06 A	-0.11 A	-0.10 E	-0.35 E
2016					-0.27 E
2017					-0.21 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

### Further Support for Sepsis Pursuit

CytoSorbents presented initial results from an investigator initiated septic shock study (n=22) conducted in Germany at the Symposium for Intensive Medicine + Intensive Care in Bremen, Germany. The single-arm study included 22 very ill patients with refractory late-stage septic shock and multiple organ failure. All standard intervention (i.e. vasopressors, artificial ventilation, dialysis, etc) had failed prior to initiating CytoSorb therapy for twelve-hours over "several days".

Initial results showed;

- 28-day survival of 41% of the patients. 28-day all-cause mortality is FDA's accepted primary endpoint in sepsis therapy studies to-date. This 41%, as CytoSorbents notes in today's PR, compares favorably to the 0% survival (100% mortality) observed in the Conrad, et al study (published in Journal of Critical Care, Aug 2015) among the group of patients (n=16) that failed to respond to standard intervention (i.e. vasopressors, artificial ventilation, dialysis, etc).
- Shock was reversed in 68% of patients
- IL-6 (high levels of which have been associated with septic shock and mortality) fell from an average mean of 87,000 pg/mL, to below 10,000 pg/mL after 24 hours of treatment. As a reminder, CytoSorbents' European sepsis study also demonstrated the ability of CytoSorb to significantly reduce IL-6 as well as a statistically significant reduction in 28-day mortality in a subgroup of patients which had very high cytokine levels (IL-6 1,000 pg/mL and/or IL-1ra 16,000 pg/mL)

While the study is too small to draw any conclusions, particularly as sepsis is a complex condition affecting heterogeneous populations making homogenous enrollment difficult, we characterize the results as positive in that it provides additional credence to the idea that CytoSorb may be effective in reducing sepsis mortality. CTSO expects to complete the full analysis and submit additional data for publication in the future. And we expect CTSO and clinicians will be conducting more sepsis-related studies which may provide more insight into the effectiveness of CytoSorb for this disease – these studies may also help narrow enrollment criteria for a pivotal U.S. study in a sepsis indication.


## FINANCIAL MODEL

### CytoSorbents Inc.

	2014 A	Q1A	Q2A	Q3A	Q4E	2015 E	2016 E	2017 E	2018 E
<b>CytoSorb Sales</b>	\$3,135.4	\$703.7	\$773.1	\$1,071.5	\$1,242.7	\$3,790.9	\$11,030.0	\$19,580.0	\$28,010.0
<i>y-o-y growth</i>	281.5%	23.6%	16.6%	3.8%	42.6%	20.9%	191.0%	77.5%	43.1%
<b>Total Royalties/Grants/Other</b>	\$987.5	\$19.4	\$190.8	\$272.2	\$211.1	\$693.5	\$1,181.8	\$665.0	\$0.0
<i>y-o-y growth</i>	-38.3%	-96.1%	-47.2%	108.4%	8217.6%	-29.8%	70.4%	-43.7%	-100.0%
<b>Revenue</b>	\$4,122.9	\$723.1	\$963.9	\$1,343.6	\$1,453.8	\$4,484.4	\$12,211.8	\$20,245.0	\$28,010.0
<i>YOY Growth</i>	70.2%	-31.9%	-5.9%	15.6%	66.4%	8.8%	172.3%	65.8%	38.4%
<b>Cost of Goods Sold</b>	\$2,133.9	\$304.5	\$465.4	\$638.8	\$667.6	\$2,076.3	\$5,225.4	\$8,005.7	\$10,643.8
<b>Gross Income</b>	\$1,989.0	\$418.6	\$498.5	\$704.8	\$786.2	\$2,408.1	\$6,986.4	\$12,239.4	\$17,366.2
<i>Gross Margin</i>	48.2%	57.9%	51.7%	52.5%	54.1%	53.7%	57.2%	60.5%	62.0%
<b>SG&amp;A</b>	\$6,836.2	\$2,179.2	\$1,924.3	\$1,988.8	\$2,334.0	\$8,426.3	\$9,654.0	\$13,237.0	\$14,341.1
<i>% SG&amp;A</i>	165.8%	301.4%	199.6%	148.0%	160.5%	187.9%	79.1%	65.4%	51.2%
<b>R&amp;D</b>	\$2,431.7	\$951.0	\$801.7	\$866.3	\$1,035.0	\$3,654.0	\$4,694.0	\$4,902.0	\$4,915.0
<i>% R&amp;D</i>	59.0%	131.5%	83.2%	64.5%	71.2%	81.5%	38.4%	24.2%	17.5%
<b>Operating Income</b>	(\$7,278.9)	(\$2,711.6)	(\$2,227.5)	(\$2,150.3)	(\$2,582.8)	(\$9,672.2)	(\$7,361.6)	(\$5,899.7)	(\$1,889.9)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-	-
<b>Total Other Expense</b>	\$2,428.5	\$2,005.3	(\$3,661.8)	\$697.1	(\$3.0)	(\$962.3)	\$0.0	\$0.0	\$0.0
<b>Pre-Tax Income</b>	(\$9,707.4)	(\$4,716.9)	\$1,434.3	(\$2,847.4)	(\$2,579.8)	(\$8,709.8)	(\$7,361.6)	(\$5,899.7)	(\$1,889.9)
<b>Taxes (benefit)</b>	(\$385.6)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
<i>Tax Rate</i>	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Preferred Dividend</b>	\$9,266.7	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
<b>Net Income</b>	(\$18,588.4)	(\$4,716.9)	\$1,434.3	(\$2,847.4)	(\$2,579.8)	(\$8,709.8)	(\$7,361.6)	(\$5,899.7)	(\$1,889.9)
<i>Net Margin</i>	-	-652.3%	148.8%	-211.9%	-177.4%	-194.2%	-60.3%	-29.1%	-6.7%
<b>EPS</b>	(\$1.29)	(\$0.19)	\$0.06	(\$0.11)	(\$0.10)	(\$0.35)	(\$0.27)	(\$0.21)	(\$0.07)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-	-
<b>Diluted Shares O/S</b>	14,441	24,394	24,769	25,038	25,350	24,888	27,000	27,700	28,200

Brian Marckx, CFA

## HISTORICAL ZACKS RECOMMENDATIONS



## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

### ANALYST DISCLOSURES

I, Brian Marckx, CFA, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

### INVESTMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

### POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

#### ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

#### ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1242 companies whose securities it covers, including securities covered by Zacks SCR:  
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.  
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.  
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 24.6%, Hold/Neutral- 52.3%, Sell/Underperform – 17.1%. Data is as of midnight on the business day immediately prior to this publication.